Novel paediatric anticoagulants: A review of the current literature

Blood Coagulation and Fibrinolysis

Volumn 21, Issue 2, 2010, Pages 144-151

  Chan, Veronica H T ^a   Monagle, Paul ^b   Massicotte, Patti ^c   Chan, Anthony K C ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Anticoagulants; Paediatrics; Thrombosis

Indexed keywords

ARGATROBAN; BLOOD CLOTTING FACTOR; DABIGATRAN; DABIGATRAN ETEXILATE; DANAPAROID; ENOXAPARIN; FONDAPARINUX; HIRULOG; LEPIRUDIN; WARFARIN;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; ARTERY EMBOLISM; ARTERY THROMBOSIS; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPISTAXIS; GROUPS BY AGE; HEMATURIA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LOADING DRUG DOSE; NASOPHARYNGEAL BLEEDING; ORAL BLEEDING; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; REPEATED DRUG DOSE; REVIEW; SUBARACHNOID HEMORRHAGE; SUPERIOR CAVA VEIN SYNDROME; THROMBOCYTE AGGREGATION; THROMBOSIS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; CHILD; CLINICAL TRIALS AS TOPIC; FACTOR XA; HUMANS; THROMBIN;

EID: 76449087965     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328335f1d2     Document Type: Review

References (54)

1. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995; 108:258S-275S.
2. Newall F, Johnston L, Ignjatovic V, Monagle P. Unfractionated heparin therapy in infants and children. Pediatrics 2009; 123:e510-e518.
3. Monagle P, Chalmers E, Chan A, DeVeber G, Kirkham F, Massicotte P, Michelson AD. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008; 133 (6 Suppl):887S-968S.
4. Dix D, Andrew M, Marzinotto V, Charpentier K, Bridge S, Monagle P, et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr 2000; 136:439-445.
5. Andrew M. Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Thromb Haemost 1995; 74:415-425.
6. Bates SM, Weitz JI. The status of new anticoagulants. Br J Haematol 2006; 134:3-19.
7. Cetta F, Graham LC, Wrona LL, Arruda MJ, Walenga JM. Argatroban use during pediatric interventional cardiac catheterization. Catheter Cariovasc Interv 2004; 61:147-149.
8. Stringer KA. Emergence of low-molecular-weight heparins in cardiology. Pharmacotherapy 1999; 19:141S-146S.
9. Dyke PC 2nd, Russo P, Mureebe L, Russo J, Tobias JD. Argatroban for anticoagulation during cardiopulmonary bypass in an infant. Paediatr Anaesth 2005; 15:328-333.
10. Hursting MJ, Dubb J, Verme-Gibboney CN. Argatroban anticoagulation in pediatric patients: a literature analysis. J Pediatr Hematol Oncol 2006; 28:4-10.
11. Malherbe S, Tsui BC, Stobart K, Koller J. Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII. Anesthesiology 2004; 100:443-445.
12. Almond CS, Harrington J, Thiagarajan R, Duncan CN, LaPierre R, Halwick D, et al. Successful use of bivalirudin for cardiac transplantation in a child with heparin-induced thrombocytopenia. J Heart Lung Transplant 2006; 25:1376-1379.
13. Young G, Tarantino MD, Wohrley J, Weber LC, Belvedere M, Nugent DJ. Pilot dose-finding and safety study of bivalirudin in infants
14. Rayapudi S, Torres A Jr, Deshpande GG, Ross MP, Wohrley JD, Young G, Tarantino MD.Bivalirudin for anticoagulation in children.Pediatr Blood Cancer2008;51:798-801
15. Zamora R. Successful anticoagulation with bivalirudin in antithrombindeficient pediatric patient undergoing stent placement. Catheter Cariovasc Interv 2006; 68:292-295.
16. Knoderer CA, Knoderer HM, Turrentine MW, Kumar M. Lepirudin anticoagulation for heparin-induced thrombocytopenia after cardiac surgery in a pediatric patient. Pharmacotherapy 2006; 26:709-712.
17. Nguyen TN, Gal P, Ransom JL, Carlos R. Lepirudin use in a neonate with heparin-induced thrombocytopenia. Ann Pharmacother 2003; 37:229-233.
18. Deitcher SR, Topoulos AP, Bartholomew JR, Kichuk-Chrisant MR. Lepirudin anticoagulation for heparin-induced thrombocytopenia. J Pediatr 2002; 140:264-266.
19. Schuepbach RA, Meili EO, Schneider E, Peter U, Bachli EB. Lepirudin therapy for thrombotic complications in congenital afibrinogenaemia. Thromb Haemost 2004; 91:1044-1046.
20. Iannoli ED, Eaton MP, Shapiro JR. Bidirectional glenn shunt surgery using lepirudin anticoagulation in an infant with heparin-induced thrombocytopenia with thrombosis. Anesth Analg 2005; 101:74-76.
21. Eikelboom JE, Weitz JI. Dabigatran etexilate for prevention of venous thromboembolism. Thromb Haemost 2009; 101:2-4.
22. Bauer KA. Targeted inhibition of coagulation: oral agents show promise in phase III trials. J Thromb Haemost 2007; 5:2175-2177.
23. Alsoufi B, Boshkov LK, Kirby A, Ibsen L, Dower N, Shen I, Ungerleider R. Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery: an emerging cause of morbidity and mortality. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2004; 7:155-171.
24. Young G, Boshkov L. Prospective study of direct thrombin inhibition with argatroban in pediatric patients requiring nonheparin anticoagulation. Blood (ASH Annual Meeting Abstracts) 2007; 110:1868.
25. Liedel JL, Panicker N, Kahana MD. Argatroban for anticoagulation in children with heparin-induced platelet antibodies [abstract]. Crit Care Med 2006; 31:A132.
26. Tcheng WY, Wong WY. Successful use of argatroban in pediatric patients requiring anticoagulant alternatives to heparin. Blood (ASH Annual Meeting Abstracts) 2004; 104:4085.
27. Kawada T, Kitagawa H, Hoson M, Okada Y, Shiomura J. Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation. Hematol Oncol Clin North Am 2000; 14:445-457.
28. Okada Y, Kawada T, Hoson M. Use of an antithrombin agent, argatroban, in two patients with extracorporeal membrane oxygenation after pediatric open heart surgery. Argatroban in two pediatric cardiac ECMO. Jpn J Thromb Hemost 2000; 11:201-204.
29. Mejak B, Giacomuzzi C, Heller E, You X, Ungerleider R, Shen I, Boshkov L. Argatroban usage for anticoagulation for ECMO on a post-cardiac patient with heparin-induced thrombocytopenia. J Extra Corpor Technol 2004; 36:178-181.
30. Potter KE, Raj A, Sullivan JE. Argatroban for anticoagulation in pediatric patients with heparin-induced thrombocytopenia requiring extracorporeal life support. J Pediatr Hematol Oncol 2007; 29:265-268.
31. Böning A, Morschheuser T, Bläse U, Scheewe J, von der Brelie M, Grabitz R, Cremer JT. Incidence of heparin-induced thrombocytopenia and therapeutic strategies in pediatric cardiac surgery. Ann Thorac Surg 2005; 79:62-65.
32. Dager WE, White RH. Low-molecular-weight heparin-induced thrombocytopenia in a child. Ann Pharmacother 2004; 38: 247-250.
33. Dager WE, Gosselin RC, Yoshikawa R, Owings JT. Lepirudin in heparininduced thrombocytopenia and extracorporeal membranous oxygenation. Ann Pharmacother 2004; 38:598-601.
34. Zikria JC, Ansell J. Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of change. Curr Opin Hematol 2009; 16:347-356.
35. Severin T, Zieger B, Sutor AH. Anticoagulation with recombinant hirudin and danaparoid sodium in pediatric patients. Semin Thromb Hemost 2002; 28:447-454.
36. Sharathkumar AA, Crandall C, Lin JJ, Pipe S. Treatment of thrombosis with fondaparinux (Arixtra) in a patient with end-stage renal disease receiving hemodialysis therapy. J Pediatr Hematol Oncol 2007; 29:581-584.
37. Boshkov LK, Kirby A, Shen I, Ungerleider RM. Recognition and management of heparin-induced thrombocytopenia in pediatric cardiopulmonary bypass patients. Ann Thorac Surg 2006; 81:S2355-S2359.
38. Young G, Nugent DJ. Use of argatroban and fondaparinux in a child with heparin-induced thrombocytopenia [abstract #1756]. Pediatr Blood Cancer 2004; 42:542. 2004.
39. Zöhrer' B, Zenz W, Rettenbacher A, Covi P, Kurnik K, Kroll H, et al. Danaparoid sodium (Orgaran) in four children with heparin-induced thrombocytopenia type II. Acta Paediatr 2001; 90:765-771.
40. Acostamadiedo JM, Iyer UG, Owen J. Danaparoid sodium. Expert Opin Pharmacother 2000; 1:803-814.
41. Wilhelm MJ, Schmid C, Kececioglu D, Möllhoff T, Ostermann H, Scheld HH. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172. Ann Thorac Surg 1996; 61:920-924.
42. Neuhaus TJ, Goetschel P, Schmugge M, Leumann E. Heparin-induced thrombocytopenia type II on hemodialysis: switch to danaparoid. Pediatr Nephrol 2000; 14:713-716.
43. Klement D, Rammos S, v Kries R, Kirschke W, Kniemeyer HW, Greinacher A. Heparin as a cause of thrombus progression. Heparin-associated thrombocytopenia is an important differential diagnosis in paediatric patients even with normal platelet counts. Eur J Pediatr 1996; 155:11-14.
44. Schiffmann H, Untrhalt M, Harms K, Figulla HR, Völpel H, Greinacher A, et al. Successful treatment of heparin-induced thrombocytopenia type II in childhood with recombinant hirudin [in German]. Monatsschr Kinderheilkd 1997; 145:606-612.
45. Weigel B, Lasky A, Krishnamurti L, Perentesis J, Neglia J, Foker J, et al. Danaparoid (Orgaran) anticoagulation of pediatric patients with heparininduced thrombocytopenia (HIT) [abstract]. J Pediatr Hematol Oncol 1999; 21:327.
46. Girisch M, Buheitel G, Ries M, Klinge J. Safe and effective use of danaparoid during cardiac catheterization in a 14 month old boy with tetralogy of Fallot and heparin-induced thrombocytopenia [abstract]. Ann Hematol 2001; 80 (Suppl 1):A20.
47. Saxon BR, Black M D, Edgell D, Noel D, Leaker M T. Pediatric heparininduced thrombocytopenia: management with Danaparoid (Orgaran). Ann Thorac Surg 1999; 68:1076-1078.
48. Ranze O, Ranze P, Magnani HN, Greinacher A. Heparin-induced thrombocytopenia in paediatric patients: a review of the literature and a new case treated with danaparoid sodium. Eur J Pediatr 1999; 158:S130-S133.
49. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with lowmolecular- weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330-1335.
50. Grabowski EF, Bussel JB. Pediatric experience with fondaparinux in deep venous thrombosis. Blood (ASH Annual Meeting Abstracts) 2006; 108:916.
51. Maurer SH, Wilimas JA, Wang WC, Reiss UM. Heparin induced thrombocytopenia and re-thrombosis associated with warfarin and fondaparinux in a child. Pediatr Blood Cancer 2009; 53:468-471.
52. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103:1838-1843.
53. Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Büttner HJ, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008; 359:688-696.
54. Eikelboom JW. Effect of fondaparinux 2.5mg once daily on mortality: a meta-analysis of phase III randomized trials of venous thromboembolism prevention. Eur Heart J 2008; 10:C8-C13.